Global Oxytocin market are set to experience a significant growth of 9.0% CAGR from 2022 to 2030, with an estimated market value of around H 83.0 Mn as of 2022. As per Future Market Insights’ projections, Postpartum type holds a substantial share of over 88.8% in 2021 within the Global market.
| Data Points | Market Insights |
|---|---|
| Market Value 2021 | USD 76.0 Million |
| Market Value 2022 | USD 83.0 Million |
| Market Value 2030 | USD 164.9 Million |
| CAGR 2022-2030 | 9.0% |
| Market Share of Top 5 Countries | 51.2% |
| Key Market Players | Pfizer Inc., Novartis AG, Ferring B.V., Fresenius Kabi LLC, Hikma Pharmaceuticals PLC, Endo International plc. (Par Sterile Products, LLC), Teva Pharmaceutical Industries Ltd., Mylan N.V., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 8.41% |
| H1, 2022 Projected | 8.96% |
| H1, 2022 Outlook | 8.96% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (+) 45 ↑ |
As compared to H1-2021, the oxytocin market is expected to surge by 45 basis point share (BPS) in H1-2022 (O), according to FMI. However, comparison analysis for the H1-2022 projected and H1-2022 outlook period reflected a decline in growth rate by nearly 10 BPS.
The use of high-quality injectable oxytocin to effectively prevent and treat postpartum haemorrhage, the main cause of maternal death worldwide, is one of the key reasons contributing to the rise in BPS.
FMI provides a comparative study of the global oxytocin market's growth rates and development prospects. Market authorization and regulatory approvals, as well as the impact of macro and industrial factors, have an impact on the market. The introduction of FDA-approved exogenous oxytocin in the antepartum phase for enhancing uterine contractions with the goal of a successful vaginal birth of the foetus is a key development in this sector.
The thermal sensitivity of oxytocin, which can result in its quality being deteriorated at several points along the health supply chain, including at the manufacturing site owing to low quality of API, a dearth of sterile production systems, or poor production methods, and during storage and transport caused by a lack of temperature regulation in the distribution network, including co-packaging, can conversely provide a restrictive growth impact on the oxytocin market.
The Oxytocin market holds nearly 6.3% of the overall USD 1.2 Bn Growth Hormones market in 2021.
The market of oxytocin on a global scale is considered extremely fragmented, with numerous local and multinational players active. Most products purchased from local players are provided by the National Government Procurement Agencies to the local governments. Thus, several developing countries are dependent upon local players, leading to an increase in focus on procurement of high volumes for lower costs.
The global oxytocin market includes an increase in the licensing activities of companies to develop new therapeutics for a range of indications.
The global oxytocin industry is set to be driven by factors including the rapidly growing global birth rate as well as the raised complications associated with birth. The overuse of caesarean delivery is expected to grow in the future which can create an unmet need of oxytocin treatment in the market. The pregnancy awareness programs offered by the local governments, NGOs and regulatory bodies are further expected to increase the awareness about the pregnancy care and healthcare setup based birth in the developing regions. The increasing awareness about pregnancy and the complications associated with it are thus the factors likely to ascend the boost in sales of oxytocin based products, thus increasing the market share growth of the oxytocin industry.
Rising demand for healthcare setup based pregnancy births and developments of high quality oxytocin therapeutics are re-shaping the therapeutic landscape in haemorrhage treatment in pregnancy. The current trend of “postpartum haemorrhage prevention” strategy is more suitable for reasons of medical need, efficacy, or desirability—has emerged as an accepted and valuable alternative to haemorrhage treatment, thus swiftly affecting the rise in oxytocin industry value.
Moreover, leading healthcare organizations at national, regional and global level are recommending the use of oxytocin as prophylactic first-line treatment for the prevention and treatment of pregnancy and birth associated haemorrhage cases globally.
The market is expected to expand at a considerable growth rate over the next eight years at a CAGR of close to 9.0%, and offer an absolute $ opportunity of USD 7.7 Million from 2021-2022. The above mentioned factors compile the sales outlook of the global oxytocin market, and are expected to raise value in the overall healthcare industry.
Principal Consultant
Increasing healthcare expenditure and per capita income offers unique opportunity for leading oxytocin manufacturers to expand their presence in the emerging market such as Africa, China and India market.
Emerging scientific and technological advancements offers potential opportunities to expand the oxytocin indication to emerging applications such as pregnancy complication, autism, social anxiety and many others. These new indications are in development phases or being preferred to use off-label but in future they could offer potential growth opportunities.
Oxytocin therapeutic with incremental innovation such as high stability of formulation, development of new convenient dosage forms, high efficacy and potency versions are expected to provide potential opportunities for the leading companies in the global oxytocin market.
Most of the market opportunities in the global oxytocin market are present in developing region with complex nature of the market. In addition, the market is highly competitive and majorly operates by local players. Hence, the collaborative approach and partnership will offer high market penetration and growth opportunities.
The availability of alternate drugs like misoprostol and magnesium sulphate for labour induction or PPH treatment could hamper the growth of oxytocin market. Moreover, misoprostol available in tablet form unlike oxytocin which is in injection form, making product more stable and easily accessible for resource-poor countries.
Manufacturers in many countries are not obtaining WHO prequalification for manufacturing of oxytocin products. This leads to production of substandard quality of drugs in the market, thus, hampering its growth.
The current market structure where large number of manufacturers are creating high price-sensitive market. That makes this market less adherent to the required regulation owing to the cost involved in the upgradation of the manufacturing facilities.
Oxytocin has been used in the dairy farming sector to enhance lactation, to speed up the ripening of fruits and vegetables. The misuse of the drug can cause deterioration of milch cattle.
The increasing complaints and misuse of the oxytocin drugs resulted in a Government implied ban on all private sector companies for manufacturing and distributing oxytocin for domestic use in India without registration and cGMP practices.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The USA dominates the North American region with a total market share of about 91.5% in 2021, and is projected to continue experiencing high growth throughout the forecast period.
The growth of this market is driven by increasing awareness regarding pregnancy products and increasing expenditure on personal care products within the country. The rising responsiveness has resulted in successful pregnancy-related awareness programs and maternal and child health has inducted itself as an essential element of the USA healthcare system.
Germany is set to exhibit a CAGR of about 6.6% in the European Oxytocin market during the forecast period. The country has essentially incorporated advanced maternity care, resulting in proliferation of sales in the European region for oxytocin products.
Presence of large industry players with key research impact upon the overall market structure, such as Novartis, in the region is further expected to present Germany as a lucrative research, development and production hub for oxytocin products in the European region throughout the forecast period.
China holds 67.3% share in the East Asia market in 2021, and is projected to increase at a CAGR rate of 6.2% during the forecast period.
The growth of the Oxytocin market in the country is attributed to the rising wave of automation and robotic assistive devices in the region of East Asia, with China as the prime contributor in the development industry for robotic devices for various intended uses, including Oxytocin for orthopaedic procedures. As a global manufacturing hub, China is likely to pose an increasing demand trend over the forecast period.
In 2021, Japan held a 26.0% share in the East Asia Oxytocin market, and is projected to expand at a CAGR of 6.9% from 2022 to 2030. The rising research interest in Japan for novel therapeutics and hormonal therapy have promoted the region of East Asia as upcoming in terms of generating spurred revenues globally.
Postpartum product types project a lucrative growth at a CAGR of 8.7% till the end of the forecast period, with a market share of over 88.8% in 2021. The applications and use of postpartum oxytocin products has resulted in the decrease of post-partum haemorrhage, and thus is being gradually adopted over the globe with a collective gain of lowered maternal mortality.
Hospital Pharmacies hold a revenue share of 63.8% in 2021 and are projected to hold a share over the forecast period with the estimation being 87.0%. A majority of procedures involving the use of Oxytocin are performed within the hospitals. Moreover, hospital networks promote the purchasing power for Oxytocin market and are thus dominant as a Distribution Channel segment.
The leading global oxytocin market players are focusing on research and development of innovative products with competitive advantages. The oxytocin market is a highly fragmented with a large number of local and multinational players operating in the market worldwide. The majority of the products in oxytocin market are procured from the local players by the national procurement agencies of the local governments.
Similarly, recent developments related to companies manufacturing Oxytocin products have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2030 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, China, Japan, South Korea, India, Malaysia, Indonesia, Thailand, Australia,New Zealand, GCC Countries, Turkey, Egypt, Nigeria, Algeria, Morocco, Kenya |
| Key Market Segments Covered | Product Distribution Channel and Region |
| Key Companies Profiled | Pfizer Inc.; Novartis AG; Ferring B.V.; Fresenius Kabi LLC; Hikma Pharmaceuticals PLC; Endo International plc. (Par Sterile Products, LLC); Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Wockhardt Ltd.; Sun Pharmaceutical Industries Ltd.; Yuhan Corporation |
| Pricing | Available upon Request |
The global Oxytocin market is worth USD 76.0 Million at present, and is set to expand 2X over the next eight years.
The Oxytocin market is expected to reach USD 164.9 Millon by the end of 2030, with sales revenue expected to register 9.0% CAGR.
Highly fragmented market, increased licensing activities and WHO prequalification are some of the key trends being witnessed in this marketplace.
The China, U. S., India, Canada and Japan are expected to drive demand for Oxytocin products.
North America is one of the key markets for Oxytocin, with the USA expected to account over 90.8% of the North American market revenue share during the forecast period.
Demand for Oxytocin in Europe is expected to register growth of 9.2% over the next seven years.
The USA, India and Canada are key producers of Oxytocin products.
Pfizer Inc., Novartis AG, Ferring B.V., Fresenius Kabi LLC, Hikma Pharmaceuticals PLC, Endo International plc. (Par Sterile Products, LLC), Teva Pharmaceutical Industries Ltd., Mylan N.V., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation are the key exporters of Oxytocin market.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Global Oxytocin Market - Pricing Analysis 6. Global Oxytocin Market Demand (in Volume) Analysis 2015 to 2021 and Forecast, 2022 to 2030 7. Global Oxytocin Market Demand (in Value or Size in USD Million) Analysis 2015 to 2021 and Forecast, 2022 to 2030 8. Market Background 9. Global Oxytocin Market Analysis 2015 to 2021 and Forecast 2022 to 2030, by Indication 9.1. Antepartum 9.2. Postpartum 10. Global Oxytocin Market Analysis 2015 to 2021 and Forecast 2022 to 2030, by Distribution Channel 10.1. Hospital Pharmacies 10.2. Drug Stores 10.3. Online Pharmacies 11. Global Oxytocin Market Analysis 2015 to 2021 and Forecast 2022 to 2030, by Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. Middle East and Africa (MEA) 11.5. East Asia 11.6. South Asia 11.7. Oceania 12. North America Oxytocin Market Analysis 2015 to 2021 and Forecast 2022 to 2030 13. Latin America Oxytocin Market 2015 to 2021 and Forecast 2022 to 2030 14. Europe Oxytocin Market 2015 to 2021 and Forecast 2022 to 2030 15. South Asia Oxytocin Market 2015 to 2021 and Forecast 2022 to 2030 16. East Asia Oxytocin Market 2015 to 2021 and Forecast 2022 to 2030 17. Oceania Oxytocin Market 2015 to 2021 and Forecast 2022 to 2030 18. Middle East and Africa Oxytocin Market 2015 to 2021 and Forecast 2022 to 2030 19. Emerging and Key Countries Oxytocin Market Analysis 20. Market Structure Analysis 21. Competition Analysis 21.1. Pfizer Inc. 21.2. Novartis AG 21.3. Ferring B.V. 21.4. Fresenius Kabi LLC 21.5. Hikma Pharmaceuticals PLC 21.6. Endo International plc. (Par Sterile Products, LLC) 21.7. Teva Pharmaceutical Industries Ltd. 21.8. Mylan N.V. 21.9. Wockhardt Ltd. 21.10. Sun Pharmaceutical Industries Ltd. 21.11. Yuhan Corporation 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Oxytocin Market
